MXCT Company Profile and Key Details
NASDAQ : MXCT
MaxCyte
$1.02
-0.06-5.56%
At Close 4:00 PM75.57
BESG ScoreESG Rating
Price Chart
Stock Price Today
MaxCyte, Inc. (MXCT) stock declined over -5.56%, trading at $1.02 on NASDAQ, down from the previous close of $1.08. The stock opened at $1.08, fluctuating between $1.02 and $1.10 in the recent session.
Stock Snapshot
1.08
Prev. Close
109.26M
Market Cap
1.02
Day Low
-3
P/E Ratio
-0.34
EPS (TTM)
-0.24
Cash Flow per Share
1.08
Open
107.12M
Number of Shares
1.095
Day High
90.22%
Free Float in %
2.24
Book Value
1.3M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 27, 2026 | 1.08 | 1.10 | 1.02 | 1.02 | 1.3M |
| Jul 24, 2026 | 1.09 | 1.13 | 1.07 | 1.08 | 504.77K |
| Jul 23, 2026 | 1.13 | 1.14 | 1.09 | 1.12 | 533.4K |
| Jul 22, 2026 | 1.22 | 1.22 | 1.12 | 1.14 | 722.6K |
| Jul 21, 2026 | 1.19 | 1.25 | 1.18 | 1.23 | 557.45K |
| Jul 20, 2026 | 1.25 | 1.27 | 1.16 | 1.17 | 983.88K |
| Jul 17, 2026 | 1.34 | 1.36 | 1.23 | 1.24 | 767.17K |
| Jul 16, 2026 | 1.42 | 1.46 | 1.30 | 1.35 | 1.04M |
| Jul 15, 2026 | 1.42 | 1.48 | 1.42 | 1.42 | 1.33M |
| Jul 14, 2026 | 1.37 | 1.44 | 1.37 | 1.42 | 1.35M |
| Jul 13, 2026 | 1.33 | 1.48 | 1.30 | 1.38 | 2.11M |
| Jul 10, 2026 | 1.28 | 1.35 | 1.28 | 1.33 | 1.42M |
| Jul 09, 2026 | 1.27 | 1.34 | 1.27 | 1.28 | 1.53M |
| Jul 08, 2026 | 1.27 | 1.31 | 1.26 | 1.28 | 1.24M |
| Jul 07, 2026 | 1.28 | 1.29 | 1.25 | 1.29 | 760.97K |
| Jul 06, 2026 | 1.22 | 1.35 | 1.21 | 1.27 | 742.44K |
| Jul 02, 2026 | 1.25 | 1.27 | 1.19 | 1.22 | 813.34K |
| Jul 01, 2026 | 1.21 | 1.25 | 1.20 | 1.23 | 487.46K |
| Jun 30, 2026 | 1.26 | 1.26 | 1.20 | 1.23 | 747.18K |
| Jun 29, 2026 | 1.25 | 1.29 | 1.21 | 1.24 | 1.24M |
Contact Details
About Company
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Company Information
| Employees | 91 |
| Beta | 1.66 |
| Sales or Revenue | $41.29M |
| 5Y Sales Change% | 0.228% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-29.4-3.20%
argenx SE$888.82REGN11.16+1.70%
Regeneron Pharmaceuticals, Inc.$667.17MDGL6.74+1.24%
Madrigal Pharmaceuticals, Inc.$551.25UTHR-0.53-0.10%
United Therapeutics Corporation$527.94VRTX1.64+0.34%
Vertex Pharmaceuticals Incorporated$479.00KRYS16.63+4.96%
Krystal Biotech, Inc.$351.82KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ONC00
BeOne Medicines AG$325.90PRAX-9.5-2.92%
Praxis Precision Medicines, Inc.$315.80LGND-3.03-1.01%
Ligand Pharmaceuticals Incorporated$297.50Company Overview
MaxCyte, Inc. (NASDAQ:MXCT) closed at $1.02 USD, losing -$0.06 (-5.56%) from the previous close of $1.08. The stock is currently mid-range between its 52-week high and low $0.64 and $2.31. With a market capitalization of about $109.26 million, MaxCyte, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.66). Key stats such as the average daily volume over the past year has been around 1.23 million shares, in line with its 52-week average. Headquartered in Rockville, MD, MaxCyte, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Maher Masoud, the company employs approximately 91 people and listed since July 29, 2021. MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
Technical Performance
MXCT has shown weak momentum, losing -11.03% over the past week and -24.84% over the past quarter, though year-to-date performance is down -21.94%. Short-term trend indicators are bullishly aligned (SMA20 0.42%, SMA50 -31.56%, SMA200 -51.78%). The stock’s 14-day RSI is 35.05 (weak momentum), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -78.52% below its high and over 23.19% above its low. Average 10-day trading volume of 766.75 thousand shares is below the 3-month average of 1.25 million, indicating normal recent market interest.
Valuation Metrics
MaxCyte, Inc. trades at a P/E ratio of -2.78, slightly below the S&P 500 average, with a price-to-sales ratio of 3.45 and a price-to-book ratio of 0.66 suggesting the stock is closer to book value. The P/FCF stands at -3.78, also below market averages.
Dividend & Fair Value
MaxCyte, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
MaxCyte, Inc. generated EPS of -$0.43 over the past year. Five-year average earnings growth is -11.37%. Wall Street analysts project EPS growth of 14.43% annually over the next five years. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.08. Next year's EPS is expected at -$6.12. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers 390.2% upside. The low target suggests 390.2% downside. The mean target is $5.00. This offers 390.2% upside. MaxCyte, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -60.0%. The prior quarter beat by -25.0%. Over the last six quarters, Apple has recorded several small beats. These include -16.67% in March 11, 2025.
Shareholding & Insider Activity
MaxCyte, Inc. has 107.12 million shares outstanding. The public float is 97.63 million shares, elevated short interest at 1.33% of float. This equals 1.41 million shares. The short ratio is 0.82 days. Institutional investors hold 69.28% of the float. Insiders own 1.59%. Casdin Partners Master Fund, L.P. holds 10.00 million shares, Casdin Eli has 10.00 million shares and Erck Stanley C has 398.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 10.14 thousand shares across 1 transactions.
Financial & Profitability Overview
On valuation metrics, MaxCyte trades at a P/E of -2.78, P/S of 3.45 and P/B of 0.66. The current ratio is 12.04 and quick ratio is 11.29. Operationally, the company’s inventory turnover is 0.82 and cash conversion cycle is 425.01 days. Debt-to-equity is 0.10, supported by a cash flow-to-debt ratio of -1.61.
Quarterly Financial Highlights
The company ended the quarter with $168.29M in cash and short-term investments, a total debt of $18.74M, and net debt of - $27.76M. Total assets were $268.27M, with equity of $232.17M. Financials further reflected weakness, with operating cash flow of - $21.69M, free cash flow of - $25.39M, and capital expenditures of - $3.70M.
Price Forecast & Outlook
Our AI price prediction model suggests that MaxCyte, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.86%, with price expected at $1.09 by August 10, 2026, within a range of $1.00 to $1.18 3-Month Outlook: Projected fall of -4.9%, reaching $0.97 by October 22, 2026, with a range of $0.86 to $1.05. 1-Year Outlook: Projected gain of 85.29%, with price at $1.89 by July 27, 2027, within a range of $1.42 to $2.06.
Key Takeaways
MaxCyte, Inc. (NASDAQ:MXCT) shares are down -21.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows MaxCyte, Inc. trading at a premium to the broader market with a P/E of -2.78. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.50, suggesting 733.33% upside. Our AI forecast model points to short-term strength (6.86% over two weeks), a medium-term fall (-4.9% over three months), and a longer-term gain (85.29% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current MaxCyte, Inc. (MXCT) stock price?
MaxCyte, Inc. (NASDAQ: MXCT) stock price is $1.02 in the last trading session. During the trading session, MXCT stock reached the peak price of $1.10 while $1.02 was the lowest point it dropped to. The percentage change in MXCT stock occurred in the recent session was -5.56% while the dollar amount for the price change in MXCT stock was - $0.06.
MXCT's industry and sector of operation?
The NASDAQ listed MXCT is part of Biotechnology industry that operates in the broader Healthcare sector. MaxCyte, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of MXCT?
Mr. James Lovgren
Senior Vice President of Global Marketing
Mr. Thomas Michael Ross
Executive Vice President of Global Sales & Marketing
Dr. Cenk Sumen
Chief Scientific Officer
Mr. Ronald Evan Holtz CPA, Ph.D.
Executive Vice President of Admin.
Mr. Douglas Arthur Doerfler
Founder, Pres, Chief Executive Officer & Executive Director
Dr. Cenk Sumen Ph.D.
Chief Scientific Officer
Mr. Maher Masoud
Executive Vice President, Gen. Counsel & Sec.
Mr. Douglas J. Swirsky CFA, CPA
Chief Financial Officer
Mr. Sean Menarguez
Director of Investor Relations
Dr. J. Stark Thompson Ph.D.
Consultant
Dr. James Brady Ph.D.
Senior Vice President of Technical Applications & Customer Support
Dr. Sarah Haecker Meeks Ph.D.
Senior Vice President of Bus. Devel.
Senior Vice President of Global Marketing
Mr. Thomas Michael Ross
Executive Vice President of Global Sales & Marketing
Dr. Cenk Sumen
Chief Scientific Officer
Mr. Ronald Evan Holtz CPA, Ph.D.
Executive Vice President of Admin.
Mr. Douglas Arthur Doerfler
Founder, Pres, Chief Executive Officer & Executive Director
Dr. Cenk Sumen Ph.D.
Chief Scientific Officer
Mr. Maher Masoud
Executive Vice President, Gen. Counsel & Sec.
Mr. Douglas J. Swirsky CFA, CPA
Chief Financial Officer
Mr. Sean Menarguez
Director of Investor Relations
Dr. J. Stark Thompson Ph.D.
Consultant
Dr. James Brady Ph.D.
Senior Vice President of Technical Applications & Customer Support
Dr. Sarah Haecker Meeks Ph.D.
Senior Vice President of Bus. Devel.
How MXCT did perform over past 52-week?
MXCT's closing price is 58.63% higher than its 52-week low of $0.64 where as its distance from 52-week high of $2.31 is -55.75%.
How many employees does MXCT have?
Number of MXCT employees currently stands at 91.
Link for MXCT official website?
Official Website of MXCT is: https://www.maxcyte.com
How do I contact MXCT?
MXCT could be contacted at phone 301 944 1700 and can also be accessed through its website. MXCT operates from 9713 Key West Avenue, Rockville, MD 20850, United States.
How many shares of MXCT are traded daily?
MXCT stock volume for the day was 1.3M shares. The average number of MXCT shares traded daily for last 3 months was 1.23M.
What is the market cap of MXCT currently?
The market value of MXCT currently stands at $109.26M with its latest stock price at $1.02 and 107.12M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep